Inhibrx Announces Participation in Upcoming Scientific Conferences

Core Insights - Inhibrx Biosciences, Inc. is set to present clinical data on its DR5 Agonist at multiple upcoming scientific conferences, highlighting its focus on novel biologic therapeutic candidates [1][2][3] Conference Presentations - The company will present at the 21st Annual Industry/Academia Precision Oncology & Radmed Symposium on November 5, 2025, discussing DR5 Agonist clinical data in various cancers [1] - At the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting from November 12-15, 2025, Inhibrx will present results from the Phase 2 ChonDRAgon Study on ozekibart (INBRX-109) in conventional chondrosarcoma [2] - The Society for NeuroOncology (SNO) 2025 Annual Meeting from November 19-23, 2025, will feature a poster presentation on the anti-tumor activity of ozekibart in GBM models [3] Company Overview - Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, utilizing diverse protein engineering methods [4] - The company was incorporated in January 2024 and has a current clinical pipeline that includes ozekibart and INBRX-106, both employing multivalent formats for optimized agonist function [4]